Device Trial Radar · NCT03900260
Clinical Evaluation of the Lenstec Softec HP1 Intraocular Lens
Last checked: Nov 19, 2026Latest source record: Feb 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
87
Actual
Start
Apr 25, 2019
Primary completion
Jul 22, 2021
Study completion Jul 22, 2021
Sponsor
- Lead sponsor
- Lenstec IncorporatedNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 3, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is designed as a post market evaluation of the Softec HP1 IOL for continuance of the CE certificate. The primary effectiveness endpoint is to evaluate the safety and performance levels produced by this IOL in patients requiring standard cataract surgery. There will be no change from standard procedure, other than 1 extra post op evaluation.
Conditions
- Aphakia
Interventions
Softec HP1 Intraocular LensDevice
The Softec HP1 IOL is a single-piece, biconvex, ultraviolet absorbing intraocular lens designed for insertion into the posterior chamber of the human eye for visual correction of Aphakia in adults over the age of 21, and as a replacement of a damaged (cataract) natural lens.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best Corrected Distance Visual Acuity (BCDVA)Time frame: 3 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Croft Shifa health Centre
Rochdale, United Kingdom
Midland Eye Institute
Solihull, United Kingdom
Sunderland Eye Infirmary
Sunderland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.